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Abstract
Background: Secretory phospholipase A2 (sPLA2) plays a pivotal role in acute respiratory distress syndrome (ARDS). This
enzyme seems an interesting target to reduce surfactant catabolism and lung tissue inflammation. Varespladib is a
specifically designed indolic sPLA2 inhibitor, which has shown promising results in animals and adults. No specific data in
pediatric ARDS patients are yet available.
Methods: We studied varespladib in broncho-alveolar lavage (BAL) fluids obtained ex vivo from pediatric ARDS patients.
Clinical data and worst gas exchange values during the ARDS course were recorded. Samples were treated with saline or
10–40–100 mM varespladib and incubated at 37uC. Total sPLA2 activity was measured by non-radioactive method. BAL
samples were subjected to western blotting to identify the main sPLA isotypes with different sensitivity to varespladib.
Results was corrected for lavage dilution using the serum-to-BAL urea ratio and for varespladib absorbance.
Results: Varespladib reduces sPLA2 activity (p,0.0001) at 10,40 and 100 mM; both sPLA2 activity reduction and its ratio to
total proteins significantly raise with increasing varespladib concentrations (p,0.001). IC50 was 80 mM. Western blotting
revealed the presence of sPLA2-IIA and –IB isotypes in BAL samples. Significant correlations exist between the sPLA2 activity
reduction/proteins ratio and PaO2 (rho = 0.63;p,0.001), PaO2/FiO2 (rho = 0.7; p,0.001), oxygenation (rho =20.6; p,0.001)
and ventilation (rho =20.4;p= 0.038) indexes.
Conclusions: Varespladib significantly inhibits sPLA2 in BAL of infants affected by post-neonatal ARDS. Inhibition seems to
be inversely related to the severity of gas exchange impairment.
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Introduction
Secretory phospholipases A2 (sPLA2; phosphatide 2-acylhydro-
lase, EC 3.1.1.4) constitute a group of enzymes responsible for
surfactant phospholipids catabolism and release of inflammatory
mediators [1,2]. sPLA2 are involved in the physiopathology of
acute respiratory distress syndrome (ARDS): in fact, sPLA2
activity is increased in the lung of affected patients [3] and
positively correlates with the predicted mortality and the degree of
lung tissue inflammation [4,5,6]. sPLA2 levels correlate negatively
with surfactant activity and compliance, as well [2,7,8]. Recently,
we reported similar findings in pediatric ARDS: sPLA2 correlates
with the clinical severity, the degree of ventilatory support and the
gas exchange impairment [9].
A wide body of literature suggests that sPLA2 would be a
potential target to treat ARDS, because its inhibition might block
the vicious cycle linking surfactant degradation and lung
inflammation [10]. While neonatal respiratory distress syndrome
(iRDS) is efficaciously treated with exogenous surfactant, the
usefulness of such therapy in ARDS beyond the neonatal age, is
not yet well established [11]. Conversely, since the sPLA2-induced
surfactant dysfunction is a typical feature of ARDS, the enzymatic
inhibition could spare the endogenous pool or protect the
exogenously administered surfactant [6,10].
Varespladib sodium (also known as A-001, LY315920, S-5920)
is a potent indole-based sPLA2 inhibitor that was optimized by
structure-based drug design to inhibit some pulmonary isotypes of
this enzyme (especially sPLA2-IIA [12]), while it is less potent
against pancreatic sPLA2-IB and has no effect on cytosolic
phospholipases [13,14]. Nowadays, this is the sPLA2 inhibitor with
more available pharmacologic data: varespladib has been intra-
venously administered in adults with septic shock [15,16] and is
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presently under advanced clinical investigation for sickle cell
disease-induced acute chest syndrome (IMPACTS trial,
NCT00434473) [17]. Varespladib methyl is the oral pro-drug of
varespladib sodium and it has been studied for chronic and acute
cardiovascular disease in two trials (PLASMA [18], FRANCIS
[19]).
Up to now, no specific data are available on pediatric ARDS
patients: the aim of the present study is to investigate the effect of
varespladib in broncho-alveolar lavage fluids obtained ex vivo from
small infants suffering from ARDS.
Materials and Methods
Subjects
This study was conducted in two academic pediatric intensive
care units (PICU) in a six months period. Eligible babies were all
infants after the first 30 days and #1 year of age, who met the
definition of ARDS according to the American-European
Consensus criteria [20]. Exclusion criteria were: 1) lung congenital
malformations; 2) need for thoracic surgery; 3) extremely critical
conditions impeding the broncho-alveolar lavage (BAL) proce-
dure; 4) patients on extra-corporeal life support. The study
protocol and consent form were approved by institutional review
boards of Universities of Rome and Padua; written informed
consent was obtained from parents or guardians before the
enrolment.
Broncho-alveolar lavage and clinical data collection
Non-bronchoscopic BAL [21] was performed within 6 h from
the fulfilling of ARDS criteria. Since this is a part of our routine
protocol for microbiological surveillance, no procedure was
performed solely for the study purposes and no change was
provided to the routine clinical assistance. As previously published
[9], BAL was performed according to the advices of the European
Respiratory Society Pediatric Task Force [21]. In details, two
sequential and separate aliquots of 1 mL/kg 0.9% NaCl warmed
at 37uC were instilled; each instillation was followed by three
respiratory cycles. A straight, snub-nosed, end-hole suction
catheter was gently advanced into the endotracheal tube, while
continuing ventilation through a Y-connector. When resistance
was met, suctioning with 50 mmHg of negative pressure was
applied. The procedure was performed with the infant’s head
turned 90u to the left and then to the right and repeated twice. The
first fluid aspirated reflecting bronchial milieu, was sent for
microbiological culture. The remaining fluid was diluted with
0.9% saline up to 5 mL and centrifuged at 3000 rpm for 109. Cell-
free supernatants were separated and immediately frozen at
280uC. Samples were excluded from further analysis if there was
visible blood contamination.
Clinical history was recorded and broncho-pulmonary dysplasia
(BPD) was diagnosed according to the United States National
Institute for Child Health and Human Development definition
[22]. All infants were ventilated using Servo-I ventilator (Maquet
Critical Care, Solna, Sweden) in pressure controlled modality,
allowing 5–6 mL/kg tidal volume. All babies have an indwelling
arterial line, as per our clinical monitoring policy. We took data
from our computerized bedside monitoring systems where vital
parameters, mechanical ventilation data and blood gas values are
recorded every 8 hours for mechanically ventilated babies, as per
our internal protocol. The worst blood gas and pH values, lowest
arterial oxygen saturation (SatO2), highest mean airway pressure
(Pa¯w) and inspired oxygen fraction (FiO2) during the ARDS
course were recorded. Lowest PaO2/FiO2 ratio was considered, as
well. Oxygenation index (OI) and a modified ventilatory index
(VI) [23] were calculated as follow: OI= [Pa¯w x FiO2/PaO2];
VI = [respiratory rate x (Pa¯w) x PaCO2/1000]. Moreover, within
6 hours from the ARDS diagnosis, single breath static respiratory
system compliance was measured during a passive exhalation,
after adequate end-inspiratory occlusion. Compliance was includ-
ed into the ‘‘Murray’s lung injury score modified for children’’ to
assess the severity of ARDS at the enrolment [24].
Laboratory methods
BAL specimens were thawed only once for the experiments,
within six months from the collection and were subdivided in 4
aliquots in which sPLA2 activity was measured after the addition
of 10, 40 or 100 mM varespladib or an equal volume of 0.9%
saline. sPLA2 total activity was measured using a high-sensitivity
non-radioactive commercially available kit (Assay Designs, Ann
Arbor, MI, USA), which uses hexadecanoylthio-1-ethylphosphor-
ylcholineas substrate. Details of this method have been described
elsewhere [25]. Varespladib or normal saline were added just after
the reaction buffer and samples were incubated at 37uC for 309
before the addition of the substrate. Coefficient of variation was
always #4%, while intra-assay and inter-assay variability were
,5% and ,9%, respectively. Varespladib was liberally provided
by Anthera Pharmaceuticals as a powder of sodium-varespladib
(A-001, Anthera Pharmaceuticals, Hayward, CA, USA) and it was
diluted in bi-distilled water at convenient concentrations. Since
varespladib solutions had a slightly yellow color, results were
corrected for the varespladib absorbance.
Urea and proteins were also measured in BAL fluids, as
previously described [9,26]; Serum urea values obtained during
the routine clinical tests in the same day of BAL procedure was
used to calculate the serum-to-BAL urea ratio. Total phospholipid
concentration was measured by analysis of lipid phosphorous, as
previously described [27]. Coefficient of variation for these assays
was always ,5%. All measurements were performed in triplicate,
by investigators blinded for the infants’ clinical data.
The presence of the main sPLA2 subtypes (sPLA2-IIA and
sPLA2-IB) that are differently targeted by varespladib, was also
investigated by western blotting. In detail, BAL samples were
lyophilized and 20 mg of BAL proteins were re-suspended in
phosphate-buffered saline and dye-sample loading buffer (50 mM
Tris–HCl, pH 6.7; 10% glycerol; 3% SDS; 1% b-mercaptoeth-
anol; 0.01% bromophenol blue). These solutions were boiled at
100uC for 109, centrifuged at 450 g for 59 at 4uC and then used for
each blot. Electrophoresis was performed using 12% SDS
polyacrilamide and then sPLA2-IIA monoclonal antibody (Cay-
man Chemical, Ann Arbor, MI, USA) or sPLA2-IB polyclonal
antibody (Santa-Cruz Biotechnology, Santa Cruz, CA, USA)
specific for human phospholipases were incubated for 2 h (dilution
1:200). The primary antibody was removed and immune-reactive
bands were incubated with a peroxidase-conjugated secondary
antibodies (at 1:2000 dilution in blocking solution) for 1 h at room
temperature. Human recombinant sPLA2IB and –IIA were used
as controls. Blotted proteins were revealed using Immobilon
Western Chemiluminescent HRP Substrate (Millipore, Billerica,
MA, USA) according with manufacturer’s protocol with maxi-
mum exposure time of 19.
Statistics and calculations
Normal distribution of data was primarily verified with Shapiro-
Wilk test and median (interquartile range) or mean 6 standard
deviation were used, as appropriate. sPLA2 activity was uncor-
rected when comparing aliquots of the same BAL specimen. Other
analyses were performed correcting for total protein content or
Varespladib and Pediatric ARDS
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serum-to-BAL urea ratio, as multiplying coefficient to transform
BAL into epithelial lining fluid (ELF) concentrations [26].
Data were analysed using Friedman and Wilcoxon tests (for post-
hoc comparisons). Ex vivo IC50 value, that is the sPLA2 remnant
activity, was determined, taking into consideration sPLA2 activity
reductions which were calculated as follows:
(sPLA2basal{sPLA2vares)=sPLA2basal(in%)
In this formula, sPLA2basal is the enzyme activity in basal
conditions (with addition of saline) and sPLA2vares is the activity
measured after the addition of increasing drug concentrations.
Spearman correlation was finally performed. Statistical analyses
were done using SPSS for Windows rel.15.0 (SPSS Inc., Chicago,
Table 1. Clinical data.
Infants 10
Age (months) 3.5 (2–6)
Weight (kg) 5 (4–8)
GA (weeks) 36 (30–39)
Male sex 6 (60)
Prematurity 5 (50)
OI 15 (9.2–21)
PaO2/FiO2 95.8 (77.7–107.8)
VI 24 (13.5–67.5)
Murray’s score 12.5 (11.7–14.5)
Duration of mechanical ventilation (days) 13.5 (7.7–17.2)
ARDS causes 5 H1N1 flu, 3 RSV bronchiolitis, 1 pneumonia, 1 severe sepsis
Co-morbidities 3 BPD, 2 Down syndrome
Data are expressed as median (i.q. range) or number (%). GA: gestational age at the birth; OI: oxygenation index; VI: ventilatory index; RSV: respiratory syncitial virus;
BPD: broncho-pulmonary dysplasia.
doi:10.1371/journal.pone.0047066.t001
Figure 1. sPLA2 activity in the four BAL aliquots treated either with normal saline (basal), or varespladib at 10, at 40 and at 100 mM.
Overall difference in median sPLA2 activity is significant at the Friedman Q-test (see text for details). p-values describe post-hoc comparison: p=0.013
between basal and varespladib10; p= 0.007 between basal and varespladib40; p= 0.005 between varespladib100 and each other measurement.
sPLA2: secretory phospholipase A2.
doi:10.1371/journal.pone.0047066.g001
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IL, USA) and p-values,0.05 were considered to be statistically
significant.
Results
During the study period ten PICU-admitted babies were
considered eligible for the study and all were enrolled. Table 1
reports basic clinical data of our population. All babies survived
and were successfully discharged from the PICUs. On average, 3
6 0.5 mL of fluid was aspirated with the non-bronchoscopic BAL
procedure (on average 60% of the instilled volume). Total proteins
and phospholipids in BAL fluids were 206 (161–290) mg/dL and
30.669.6 mg/mL, respectively. All BAL samples were sterile at the
microbiological culture and did not show visible blood contam-
ination.
sPLA2 activity in all BAL aliquots, added with either saline or
increasing varespladib concentrations, are depicted in Fig. 1. An
overall significant difference (p,0.0001) exists among sPLA2
activity in basal conditions [37.7 (31.8–48.5) IU/mL], after
addition of 10 mM [34.1 (24.9–42.5) IU/mL], 40 mM (28.4
(25.5–32.3) IU/mL] and 100 mM of varespladib [7.7 (5.4–12.5)
IU/mL]. Significant differences are evident at the post-hoc
comparisons, except that between enzymatic levels measured with
10 and 40 mM of varespladib.
Inverse significant correlation was found between protein level
and sPLA2 activity reduction at 10 mM of varespladib
(rho=20.906; see Fig. 2). Conversely, no significant relationships
were found at 40 (rho=20.25; p=0.49) and 100 mM of
varespladib (rho=20.05; p=0.88).
Figure 2. Negative correlation between the reduction of sPLA2 total activity and protein content. Grey lines represent linear regression
line and its 95% confidence interval (rho = 0.906; p,0.001; R2 = 0.73).
doi:10.1371/journal.pone.0047066.g002
Figure 3. Western blot assay of BAL samples for the two main sPLA2 isotypes that respond differently to varespladib inhibition
(sPLA2-IB and sPLA2-IIA). Illustrative results of four ARDS patients (and human recombinant proteins, as controls) are shown. All patients presents
sPLA2-IIA, while some also shown the presence of the isotype –IB. sPLA2: secretory phospholipase A2.
doi:10.1371/journal.pone.0047066.g003
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Correlations were also found between sPLA2 activity reduction-
to-ELF proteins ratio and VI (rho=20.4; p=0.038), OI
(rho=20.6; p,0.001), PaO2/FiO2 ratio (rho= 0.7;p,0.001) and
PaO2 (rho= 0.63; p,0.001). No other correlations were found.
Figure 3 shows the western blotting assay of BAL samples for
four patients. A relevant amount of sPLA2-IIA was present in all
patients, while some also express a lower amount of the isotype –
IB.
Discussion
Varespladib significantly inhibits sPLA2 in BAL of infants
affected by post-neonatal ARDS and the inhibition seems to be
inversely related to the severity of gas exchange impairment. The
present findings seem consistent with another study [9] reporting
significant correlations between sPLA2, the degree of ventilatory
support and the gas exchange impairment. These findings, though
intriguing, are not describing the clinical administration of
varespladib to patients. In fact, the interaction with cells and
whole tissues may influence the effect of varespladib and,
consequently, the surfactant function. However, these findings
allow to speculate on interesting application of varespladib and
future research steps.
When administered intravenously in rabbit acute lung injury,
varespladib was able to improve gas exchange, compliance and
reduce inflammatory mediators [5,6]. Recently, we were able to
report a similar effect of varespladib in some types of neonatal lung
injury, such as hyaline membrane disease or meconium aspiration
syndrome, that are very different from ARDS [28,29]. We now
add novel findings for this particular field: in fact, paediatric
ARDS is well distinct from neonatal lung injuries. It shares some
features with the adult form of the syndrome but differ in
mortality, triggers and epidemiology, needing specific paediatric
investigation [29].
Ex vivo IC50 of varespladib in BAL from ARDS infants is
roughly well over the nanomolar range described in other
experiments and this may be explained for three reasons [13].
First, high protein levels are present in the alveoli of ARDS
patients and this could reduce the amount of free varespladib. In
fact, varespladib binds such proteins and this prevents it from
reaching the sPLA2 catalytic site, as it has been shown using
animal data [13]. The inverse correlation between sPLA2 activity
reduction and protein content is significant only at the lowest
varespladib concentrations, while correlation coefficient is reduc-
ing with increasing doses. This is consistent with data already
published about varespladib-protein binding [13] and suggests that
high varespladib dosing may overcome this problem. In fact,
animals with lung injury clearly showed a dose-dependent effect
[5,6]. Second, the different proportions of sPLA2 isotypes
expressed in these young patients may be relevant: in fact, we
clearly show that some patients also have a detectable amount
sPLA2-IB, which is less sensible to varespladib inhibition [13].
Third, different type and amount of surfactant phospholipids
present in the diseased alveoli may also play a role [30,31]. Total
phospholipid content in our population is low and consistent with
other ARDS patients [31] albeit qualitative alteration of
phospholipid pool may deserve to be studied. Clearly, further
research is needed to clarify the main factor affecting the
varespladib inhibition.
sPLA2 seems to be less inhibited in samples associated with
severe gas exchange impairment. OI, PaO2/FiO2 ratio and VI
describe both oxygenation and ventilation: both components of
gas exchange are impaired and inversely correlated with the
sPLA2 activity reduction/proteins ratio. This phenomenon could
be related to a higher enzyme production or to a change in the
expression profile of different isotypes requiring much varespladib
to be inhibited. Alternatively, a greater degree of inflammation
and more proteins filling the alveoli could interfere with the
enzymatic inhibition. Finally, the onset of a fibro-proliferative
process could influence the inhibition. sPLA2 correlates with lung
stiffness [7], which in its turn is associated with collagen activation
and deposition [8]. This fibrotic process is known to correlate
negatively with clinical outcome [32,33] and, in fact, dying
patients have higher alveolar sPLA2 levels [4].
Some particular characteristics of our population should be
noticed. First, patients were mostly affected by quite severe forms
of ARDS (as shown by the low phospholipid content, the severe
PaO2/FiO2 ratio, OI, VI, Murray’s score and the long duration of
mechanical ventilation). Actually, ARDS is a complex syndrome
with many possible causes and these may affect the permeability of
the alveolar/blood barrier causing various degree of lung oedema
[4,9]. The different causes of ARDS may have influenced our
findings. For instance, three of our cases were induced by RSV
infection. RSV, the commonest cause of viral respiratory infections
in infants [34], triggers an enzymatic cross-talk inducing the over-
expression of the cytosolic phospholipase A2 [35], which in its turn
may boost the production of sPLA2, both directly and through its
inflammatory products [36,37].
Varespladib is clinically interesting because it is a sPLA2
inhibitor with wide existing pharmacological data, having already
undertaken phase II/III clinical studies in adults (in both the oral
and intravenous formulations), for different clinical indications
[15–19]. Such drug might achieve the double goal of: 1) reducing
lung tissue inflammation, and 2) sparing the endogenous pool of
surfactant. This is an unique key point in acute lung injury and
ARDS, because both processes (inflammation and surfactant
catabolism) are linked by sPLA2 [10]. Such link is confirmed by
the lower levels of Clara Cell Secretory Protein, the natural sPLA2
inhibitor, found in BAL of adults with ARDS [38]. Varespladib
could surrogate locally this natural inhibition, while other
therapeutics fail. In fact, steroid treatment has not definite
advantages in adults with ARDS [39] and may have significant
side effects in small infants; moreover, in rabbits, steroids
effectively reduce inflammation, but fail to reduce sPLA2 activity
and to protect surfactant [40].
We acknowledge some study limitations. Ours is a preliminary
experience on a small population, sampled only once at the
diagnosis of ARDS. However, our population size is similar to the
studies performed in this field in adults [3,4] and we provide
definite data from our monitoring system to study the relationships
with clinical variables. Larger studies including ARDS induced by
several causes should verify if the underlying diseases, type of
ARDS or other clinical characteristics may influence the inhibition
of sPLA2. Similarly, the whole sPLA2 pathway, profile of
expression of enzyme isotypes, role of different phospholipids
and impending fibro-proliferative process deserve to be studied.
Our study is based on a cell-free model, therefore no cellular
interactions may be taken into account. In conclusion, varespladib
may significantly inhibit sPLA2, providing efficacious enzyme- and
tissue-specific anti-inflammatory action at lung level. Specific
studies should address the above described issues in animal
models, to define the main factors affecting sPLA2 inhibition and
to also investigate the best timing and dosing of administration.
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